OPKO Health, Inc. Finance Lease, Liability, to be Paid, after Year Five
OPKO Health, Inc. (OPK) had Finance Lease, Liability, to be Paid, after Year Five of $1.73 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Commitment and Contingencies › Finance Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive · last filed 2026-02-26
- 2025-12-31: Finance Lease, Liability, to be Paid, after Year Five $1.73M.
- 2024-12-31: Finance Lease, Liability, to be Paid, after Year Five $1.81M.
- 2023-12-31: Finance Lease, Liability, to be Paid, after Year Five $1.94M.
- 2022-12-31: Finance Lease, Liability, to be Paid, after Year Five $1.93M.
| Period end | Finance Lease, Liability, to be Paid, after Year Five |
|---|---|
| 2025-12-31 | $1.73M 10-K · filed 2026-02-26 |
| 2024-12-31 | $1.81M 10-K · filed 2025-03-03 |
| 2023-12-31 | $1.94M 10-K · filed 2024-03-01 |
| 2022-12-31 | $1.93M 10-K · filed 2023-02-27 |
| 2021-12-31 | $0.00 10-K · filed 2022-03-01 |
| 2020-12-31 | $0.00 10-K · filed 2021-02-18 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-06 |
| 2019-12-31 | $0.00 10-K · filed 2020-03-02 |
| 2019-09-30 | $203.00K 10-Q · filed 2019-11-05 |
| 2019-06-30 | $419.00K 10-Q · filed 2019-08-07 |
| 2019-03-31 | $201.00K 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |